Avanos Medical (NYSE:AVNS) Reaches New 1-Year Low – What’s Next?

Avanos Medical, Inc. (NYSE:AVNS) hit a new 52-week low during trading on Wednesday . The stock traded as low as $13.64 and last traded at $15.84, with a volume of 7687 shares. The stock had previously closed at $15.56.

Wall Street Analyst Weigh In

Separately, StockNews.com cut Avanos Medical from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 3rd.

Avanos Medical Trading Up 4.9 %

The company has a market capitalization of $750.11 million, a PE ratio of 47.59 and a beta of 0.98. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The stock has a fifty day moving average of $16.15 and a two-hundred day moving average of $19.73.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.40 by $0.03. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. As a group, sell-side analysts anticipate that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avanos Medical

Hedge funds have recently made changes to their positions in the company. FMR LLC boosted its position in shares of Avanos Medical by 34.6% during the third quarter. FMR LLC now owns 133,844 shares of the company’s stock valued at $3,216,000 after purchasing an additional 34,421 shares in the last quarter. Barclays PLC boosted its position in shares of Avanos Medical by 446.2% during the third quarter. Barclays PLC now owns 96,194 shares of the company’s stock valued at $2,311,000 after purchasing an additional 78,583 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Avanos Medical by 12.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 108,470 shares of the company’s stock valued at $2,607,000 after purchasing an additional 11,613 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Avanos Medical by 6.9% during the third quarter. JPMorgan Chase & Co. now owns 69,571 shares of the company’s stock valued at $1,672,000 after purchasing an additional 4,472 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in Avanos Medical by 35.8% during the third quarter. Jane Street Group LLC now owns 65,650 shares of the company’s stock valued at $1,578,000 after buying an additional 17,306 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.